53 results about "Insulin tolerance" patented technology

An increase in body fat is one of main causes of life-style-related diseases such as hypertension, insulin tolerance, and hyperlipemia. A composition for body fat reduction is provided which inhibits body fat from decreasing or increasing and which is effective in the treatment and prevention of adult diseases a cause of which is body fat. Also provided are a medicine and a food each containing the composition. [MEANS FOR SOLVING PROBLEMS] The composition for body fat reduction comprises (A) astaxanthin and (B) at least one of an active ingredient, an adsorbent, and a solubilizer. Alternatively, it comprises (A) a Haematococcus pluvialis extract containing astaxanthin and (B) at least one of an active ingredient, an adsorbent, and a solubilizer.

The invention relates to a method for constructing an insulin resistance animal model. A Sprague Dawley rat is injected with glucose oxidase (400U / kg weight) through tail vein injection to induce to generate insulin resistance. The statistical analysis of ghlcose tolerance and insulin tolerance and the detection of insulin signal transduction prove that the glucose oxidase constructed insulin resistance animal model is feasible, and can serve as a research model for insulin resistance, the pathogenesis of type 2 diabetes and a medicine function mechanism. Compared with the conventional model constructing technology, the method has the advantages of simple modeling method, high modeling efficiency, low cost, short period, high repeatability and the like.

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a method of preparing same and a pharmaceutical composition for preventing and treating metabolic disease including same as an effective ingredient. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has an excellent effect on activation of GPR40 protein and thus has excellent promoting effect of insulin secretion; is nontoxic when co-administrated with other drugs and is possibly co-administrated with other drugs; and has excellent effective effect of activating GPR40 protein in vivo. Therefore, a composition including the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof may be availably used in a pharmaceutical composition for preventing and treating metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin tolerance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X, etc.

The invention discloses an application and construction method of a high-selenium induced insulin resistance animal model. The application and construction method comprises the following steps of: feeding 100mug / kg-200ug / kg of selenium to the stomach of an SD (Sprague Dawley) rat every day; and six weeks later, obtaining the insulin resistance animal model. According to the statistic analysis of glucose tolerance and insulin tolerance, insulin signal transduction and gluconeogenesis key enzyme test, the construction of the insulin resistance animal model by utilizing sodium selenite is feasible; and the insulin resistance animal model can be used as a high-selenium induced insulin resistance animal model and a pathogenesis and drug action mechanism research model of diabetes mellitus II. The insulin resistance rat model constructed by the application and the construction method disclosed by the invention has the advantages of simpleness in modeling method, high model establishing success rate, low cost, short period, good reproducibility and the like.

The invention belongs to the field of medicine and pharmacy, and relates to the new medical application of hydrogen sulfide and its donor sodium hydrosulfide in pharmacy, in particular to the application of hydrogen sulfide and its donor sodium hydrosulfide in preparing medicines for treating diabetes. The present invention uses exogenous hydrogen sulfide and its donor sodium hydrogen sulfide NaHS for insulin sensitization and tests for lowering blood sugar and increasing insulin levels for type II diabetes. Through correlation tests between skeletal muscle and adipocytes and insulin resistance, diabetic insulin The animal model of resistance conducts insulin tolerance test, glucose consumption test, animal model test of diabetes insulin resistance, and NaHS intervention animal experiment, etc. The results show that: NaHS can play a role in promoting glucose uptake in the presence of insulin, showing enhanced Insulin action. The hydrogen sulfide and its donor sodium hydrosulfide can be used as an insulin sensitizer and a drug for lowering blood sugar and increasing insulin level for type II diabetes.